BiotechTube

AZD2281

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasm Metastasis

Conditions

Neoplasm Metastasis

Trial Timeline

Apr 1, 2008 → Oct 1, 2008

NCT ID
NCT00633269

About AZD2281

AZD2281 is a phase 1 stage product being developed by AstraZeneca for Neoplasm Metastasis. The current trial status is completed. This product is registered under clinical trial identifier NCT00633269. Target conditions include Neoplasm Metastasis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (3)

NCT IDPhaseStatus
NCT00777582Phase 1Active
NCT00679783Phase 2Completed
NCT00633269Phase 1Completed

Competing Products

20 competing products in Neoplasm Metastasis

See all competitors
ProductCompanyStageHype Score
AB0024Gilead SciencesPhase 1
32
TTI-237PfizerPhase 1
32
852APfizerPhase 1
32
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
32
LY2780301Eli LillyPhase 1
33
PemetrexedEli LillyPhase 2
52
pemetrexed + cisplatinEli LillyPhase 1/2
41
IMC-3C5Eli LillyPhase 1
33
LY3295668Eli LillyPhase 1/2
41
Abemaciclib + ClarithromycinEli LillyPhase 1
33
Abemaciclib + FulvestrantEli LillyPhase 2
52
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
41
Fulvestrant + AbemaciclibEli LillyPhase 2
52
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
77
Prexasertib + Cisplatin + Cetuximab + G-CSF + Pemetrexed + Fluorouracil + LY3023414 + LeucovorinEli LillyPhase 1
33
LY2784544Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
enzastaurinEli LillyPhase 2
52
enzastaurin + gemcitabineEli LillyPhase 2
52
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
33

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85